Cargando…
Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma
The aim of this study was to evaluate the diagnostic and differential diagnostic power of serum N-glycans for light chain multiple myeloma (LCMM). A total of 167 cases of subjects, including 42 LCMM, 42 IgG myeloma, 41 IgA myeloma, and 42 healthy controls were recruited in this study. DNA sequencer-...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468189/ https://www.ncbi.nlm.nih.gov/pubmed/26075387 http://dx.doi.org/10.1371/journal.pone.0127022 |
_version_ | 1782376459737759744 |
---|---|
author | Chen, Jie Fang, Meng Zhao, Yun-Peng Yi, Chang-Hong Ji, Jun Cheng, Cheng Wang, Meng-Meng Gu, Xing Sun, Quan-Sheng Chen, Xiao-Ling Gao, Chun-Fang |
author_facet | Chen, Jie Fang, Meng Zhao, Yun-Peng Yi, Chang-Hong Ji, Jun Cheng, Cheng Wang, Meng-Meng Gu, Xing Sun, Quan-Sheng Chen, Xiao-Ling Gao, Chun-Fang |
author_sort | Chen, Jie |
collection | PubMed |
description | The aim of this study was to evaluate the diagnostic and differential diagnostic power of serum N-glycans for light chain multiple myeloma (LCMM). A total of 167 cases of subjects, including 42 LCMM, 42 IgG myeloma, 41 IgA myeloma, and 42 healthy controls were recruited in this study. DNA sequencer-assisted fluorophore-assisted capillary electrophoresis (DSA-FACE) was applied to determine the quantitive abundance of serum N-glycans. The core fucosylated, bisecting and sialylated modifications were analyzed in serum of LCMM patients (n=20) and healthy controls (n=20) randomly selected from the same cohort by lectin blot. Moreover, serum sialic acid (SA) level was measured by enzymatic method. We found two N-glycan structures (NG1A2F, Peak3; NA2FB, Peak7) showed the optimum diagnostic efficacy with area under the ROC curve (AUC) 0.939 and 0.940 between LCMM and healthy control. The sensitivity and specificity of Peak3 were 88.1% and 92.9%, while Peak7 were 92.9% and 97.6%, respectively. The abundance of Peak3 could differentiate LCMM from IgG myeloma with AUC 0.899, sensitivity 100% and specificity 76.2%, and Peak7 could be used to differentiate LCMM from IgA myeloma with AUC 0.922, sensitivity 92.9% and specificity 82.9%. Serum SA level was significantly higher in patients with LCMM than that in healthy controls. Moreover, the decreased core fucosylation, bisecting and increased sialylation characters of serum glycoproteins were observed in patients with LCMM. We concluded that serum N-glycan could provide a simple, reliable and non-invasive biomarker for LCMM diagnosis and abnormal glycosylation might imply a new potential therapeutic target in LCMM. |
format | Online Article Text |
id | pubmed-4468189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44681892015-06-25 Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma Chen, Jie Fang, Meng Zhao, Yun-Peng Yi, Chang-Hong Ji, Jun Cheng, Cheng Wang, Meng-Meng Gu, Xing Sun, Quan-Sheng Chen, Xiao-Ling Gao, Chun-Fang PLoS One Research Article The aim of this study was to evaluate the diagnostic and differential diagnostic power of serum N-glycans for light chain multiple myeloma (LCMM). A total of 167 cases of subjects, including 42 LCMM, 42 IgG myeloma, 41 IgA myeloma, and 42 healthy controls were recruited in this study. DNA sequencer-assisted fluorophore-assisted capillary electrophoresis (DSA-FACE) was applied to determine the quantitive abundance of serum N-glycans. The core fucosylated, bisecting and sialylated modifications were analyzed in serum of LCMM patients (n=20) and healthy controls (n=20) randomly selected from the same cohort by lectin blot. Moreover, serum sialic acid (SA) level was measured by enzymatic method. We found two N-glycan structures (NG1A2F, Peak3; NA2FB, Peak7) showed the optimum diagnostic efficacy with area under the ROC curve (AUC) 0.939 and 0.940 between LCMM and healthy control. The sensitivity and specificity of Peak3 were 88.1% and 92.9%, while Peak7 were 92.9% and 97.6%, respectively. The abundance of Peak3 could differentiate LCMM from IgG myeloma with AUC 0.899, sensitivity 100% and specificity 76.2%, and Peak7 could be used to differentiate LCMM from IgA myeloma with AUC 0.922, sensitivity 92.9% and specificity 82.9%. Serum SA level was significantly higher in patients with LCMM than that in healthy controls. Moreover, the decreased core fucosylation, bisecting and increased sialylation characters of serum glycoproteins were observed in patients with LCMM. We concluded that serum N-glycan could provide a simple, reliable and non-invasive biomarker for LCMM diagnosis and abnormal glycosylation might imply a new potential therapeutic target in LCMM. Public Library of Science 2015-06-15 /pmc/articles/PMC4468189/ /pubmed/26075387 http://dx.doi.org/10.1371/journal.pone.0127022 Text en © 2015 Chen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Chen, Jie Fang, Meng Zhao, Yun-Peng Yi, Chang-Hong Ji, Jun Cheng, Cheng Wang, Meng-Meng Gu, Xing Sun, Quan-Sheng Chen, Xiao-Ling Gao, Chun-Fang Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma |
title | Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma |
title_full | Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma |
title_fullStr | Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma |
title_full_unstemmed | Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma |
title_short | Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma |
title_sort | serum n-glycans: a new diagnostic biomarker for light chain multiple myeloma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468189/ https://www.ncbi.nlm.nih.gov/pubmed/26075387 http://dx.doi.org/10.1371/journal.pone.0127022 |
work_keys_str_mv | AT chenjie serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT fangmeng serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT zhaoyunpeng serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT yichanghong serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT jijun serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT chengcheng serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT wangmengmeng serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT guxing serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT sunquansheng serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT chenxiaoling serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma AT gaochunfang serumnglycansanewdiagnosticbiomarkerforlightchainmultiplemyeloma |